Tourmaline Bio, Inc.
TRML · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $412 | $391 | $523 | $662 |
| - Cash | $31 | $35 | $31 | $35 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $381 | $356 | $493 | $628 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | – | – | 50% | – |
| EBITDA | -$26 | -$23 | -$22 | -$24 |
| % Margin | – | – | -55,565% | – |
| Net Income | -$23 | -$23 | -$22 | -$20 |
| % Margin | – | – | -55,587.5% | – |
| EPS Diluted | -0.9 | -0.89 | -0.86 | -0.78 |
| % Growth | -1.1% | -3.5% | -10.3% | – |
| Operating Cash Flow | -$20 | -$22 | -$21 | -$23 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$20 | -$22 | -$21 | -$23 |